In another phase II trial for R/R AML, tucidinostat, decitabine, cytarabine, idarubicin, and granulocyte-colony stimulating factor (CDIAG) were used in a double epigenetic priming regimen. Here, CSF3 is linked to acute myeloid leukemia.